Latchana Nicholas, Hirpara Dhruvin H, Hallet Julie, Karanicolas Paul J
Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Division of General Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Langenbecks Arch Surg. 2019 Feb;404(1):1-9. doi: 10.1007/s00423-018-1746-2. Epub 2019 Jan 3.
Several modalities exist for the management of hepatic neoplasms. Resection, the most effective approach, carries significant risk of hemorrhage. Blood loss may be corrected with red blood cell transfusion (RBCT) in the short term, but may ultimately contribute to negative outcomes.
Using available literature, we seek to define the frequency and risk factors of blood loss and transfusion following hepatectomy. The impact of blood loss and RBCT on short- and long-term outcomes is explored with an emphasis on peri-operative methods to reduce hemorrhage and transfusion.
Following hepatic surgery, 25.2-56.8% of patients receive RBCT. Patients who receive RBCT are at increased risk of surgical morbidity in a dose-dependent manner. The relationship between blood transfusion and surgical mortality is less apparent. RBCT might also impact long-term oncologic outcomes including disease recurrence and overall survival. Risk factors for bleeding and blood transfusion include hemoglobin concentration < 12.5 g/dL, thrombocytopenia, pre-operative biliary drainage, presence of background liver disease (such as cirrhosis), coronary artery disease, male gender, tumor characteristics (type, size, location, presence of vascular involvement), extent of hepatectomy, concomitant extrahepatic organ resection, and operative time. Strategies to mitigate blood loss or transfusion include pre-operative (iron, erythropoietin), intra-operative (vascular occlusion, parenchymal transection techniques, hemostatic agents, antifibrinolytics, low central pressure, hemodilution, autologous blood recycling), and post-operative (normothermia, correction of coagulopathy, optimization of nutrition, restrictive transfusion strategy) methods.
Blood loss during hepatectomy is common and several risk factors can be identified pre-operatively. Blood loss and RBCT during hepatectomy is associated with post-operative morbidity and mortality. Disease-free recurrence, disease-specific survival, and overall survival may be associated with blood loss and RBCT during hepatectomy. Attention to pre-operative, intra-operative, and post-operative strategies to reduce blood loss and RBCT is necessary.
肝肿瘤的治疗有多种方式。肝切除术是最有效的方法,但有大出血的重大风险。短期内可通过输注红细胞(RBCT)纠正失血,但最终可能导致不良后果。
利用现有文献,我们试图确定肝切除术后失血和输血的频率及危险因素。探讨失血和RBCT对短期和长期结局的影响,重点关注减少出血和输血的围手术期方法。
肝切除术后,25.2%至56.8%的患者接受RBCT。接受RBCT的患者手术并发症风险呈剂量依赖性增加。输血与手术死亡率之间的关系不太明显。RBCT还可能影响包括疾病复发和总生存期在内的长期肿瘤学结局。出血和输血的危险因素包括血红蛋白浓度<12.5 g/dL、血小板减少、术前胆道引流、存在基础肝病(如肝硬化)、冠状动脉疾病、男性、肿瘤特征(类型、大小、位置、血管受累情况)、肝切除范围、同期肝外器官切除以及手术时间。减少失血或输血的策略包括术前(铁剂、促红细胞生成素)、术中(血管阻断、实质切开技术、止血剂、抗纤溶药物、低中心静脉压、血液稀释、自体血回输)和术后(正常体温、纠正凝血功能障碍、优化营养、限制性输血策略)方法。
肝切除术中失血常见,术前可识别多种危险因素。肝切除术中失血和RBCT与术后并发症及死亡率相关。无病复发、疾病特异性生存期和总生存期可能与肝切除术中失血和RBCT有关。关注术前、术中和术后减少失血和RBCT的策略很有必要。